Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease
Movement Disorders · 05.11.2026
DOI: 10.1002/mds.70573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 05.11.2026. Verfasst von Anastasia Kuzkina und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Movement Disorders and Ann Romney Center for Neurologic Diseases, Department of Neurology, Mass General Brigham and Harvard Medical Schoo…. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Parkinson Disease Association, Mission MSA, Brigham Research Institute.
Abstract (Originalsprache)
Background
Misdiagnoses of multiple system atrophy (MSA) and Parkinson's disease (PD) remain common.
Objective
The objective of the study was to develop a skin α‐synuclein seed amplification assay (αSyn‐SAA) for detecting pathological α‐synuclein and distinguishing MSA from PD.
Methods
In this blinded, cross‐sectional study, 308 skin biopsies from 117 participants were analyzed using a standardized thioflavin T fluorescence‐based αSyn‐SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 progressive supranuclear palsy (PSP) cases. Kinetic parameters were analyzed to differentiate PD from MSA, and matched skin cerebrospinal fluid (CSF)/magnetic resonance imaging (MRI) analyses were performed. Assay thresholds were predefined using brain lysates from neuropathologically confirmed cases. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results αSyn‐SAA detected synucleinopathy (PD or MSA) with 82.2% sensitivity and 90% specificity versus controls. Receiver operating characteristic (ROC) analysis showed that maximum fluorescence ( F max , area under the curve [AUC] = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. SAA positivity correlated with rapid eye movement (REM) sleep behavior disorder (RBD) in both disorders. Among SAA‐positive cases, the 50% mean F max cutoff correctly classified the underlying synucleinopathy in 81.7% of cases (49 of 60). Disease‐specific kinetic and structural signatures were reproducible across laboratories and αSyn substrate batches and were supported by concordant findings in a subset of skin samples matched to CSF, MRI data, and postmortem brain tissue.
Conclusion
Skin αSyn‐SAA detects pathological α‐synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties, supporting its potential as a biomarker to distinguish among synucleinopathies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Autor:innen und Institutionen
- Division of Movement Disorders and Ann Romney Center for Neurologic Diseases, Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA.
- American Parkinson Disease Association Center for Advanced Research and MSA Center of Excellence, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.
- Harvard Biomarkers Study, P+A+MSA Clinic and MyTrial Program, Mass General Brigham, Boston, Massachusetts, USA.
- Department of Neuropathology, Institute of Pathology, University of Würzburg, Josef-Schneider-Str. 2, Würzburg, Germany.
ORCID-Profile: Anastasia Kuzkina, Diego Rodriguez, Alain Ndayisaba, Lisa Harder-Rauschenberger, Robert Blum, Jens Volkmann, Barbara K Changizi, Kathrin Doppler, Vikram Khurana
Förderung
- American Parkinson Disease Association
- Mission MSA
- Brigham Research Institute
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- Mass General Brigham MyTrial, Rosenbaum Family Personalized Parkinson's Initiative and Multiple System Atrophy Funds
- NIH HHS
Zitieren
APA
Kuzkina, A., Rodriguez, D., Panzer, C., Ndayisaba, A., Kohl, A., Rai, S., Gilbert, B., Hammerschlag, B., Shen, K., Harder-Rauschenberger, L., Laun, O., Meehan, J., Perumalla, S., Salabasidou, E., Jones, K., Ceku, D., Blum, R., Knorr, S., Monoranu, C. M., …, & Khurana, V. (2026). Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.70573
Vancouver
Kuzkina A, Rodriguez D, Panzer C, Ndayisaba A, Kohl A, Rai S, et al. Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease. Movement Disorders. 2026. doi:10.1002/mds.70573
BibTeX
@article{Kuzkina2026,
author = {Kuzkina, Anastasia and Rodriguez, Diego and Panzer, Celine and Ndayisaba, Alain and Kohl, Antonia and Rai, Shreya and Gilbert, Breelyn and Hammerschlag, Bruno and Shen, Karie and Harder-Rauschenberger, Lisa and Laun, Olivia and Meehan, Julia and Perumalla, Sucika and Salabasidou, Elena and Jones, Kristie and Ceku, Dalina and Blum, Robert and Knorr, Susanne and Monoranu, Camelia M and Sommer, Claudia and Volkmann, Jens and Changizi, Barbara K and Doppler, Kathrin and Khurana, Vikram},
title = {Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease},
journal = {Movement Disorders},
year = {2026},
doi = {10.1002/mds.70573}
}
EUVIMED